Europe CRO Market

ID: MRFR/HC/11110-HCR
128 Pages
Vikita Thakur
Last Updated: April 06, 2026
Europe CRO Market Research Report Information By Service Type (Early Phase Development Services, Clinical, Laboratory Service, and Others), By Application (Oncology, Neurology, Cardiology, Infectious Disease, Metabolic Disorder, Renal/Nephrology, and Others), By End-user (Pharmaceutical & Biotech Companies, Medical Device Companies, Academic & Research Institutes, and Others), And By Region (Germany, France, UK, Italy, Spain, and Rest of Europe) –Market Forecast Till 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Europe CRO Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)6.0%
2024 Market Size$ 23.6 Billion
2025 Market Size$ 25.17 Billion
2035 Market Size$ 44.81 Billion

Key Players

IQVIA
Covance
PAREXEL International
Charles River Laboratories
Syneos Health
Medpace
Trends
  • Increased Demand for Specialized Services
  • Emphasis on Patient-Centric Approaches
  • Integration of Digital Technologies
Opportunities
  • Expansion of Outsourcing Trends
  • Growing Biopharmaceutical Sector
  • Regulatory Support and Compliance
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Service Type (USD Billion)
      1. 4.1.1 Clinical Trials
      2. 4.1.2 Preclinical Services
      3. 4.1.3 Laboratory Services
      4. 4.1.4 Consulting Services
    2. 4.2 Healthcare, BY Therapeutic Area (USD Billion)
      1. 4.2.1 Oncology
      2. 4.2.2 Cardiology
      3. 4.2.3 Neurology
      4. 4.2.4 Infectious Diseases
    3. 4.3 Healthcare, BY End User (USD Billion)
      1. 4.3.1 Pharmaceutical Companies
      2. 4.3.2 Biotechnology Companies
      3. 4.3.3 Medical Device Companies
      4. 4.3.4 Academic Institutions
    4. 4.4 Healthcare, BY Study Phase (USD Billion)
      1. 4.4.1 Phase I
      2. 4.4.2 Phase II
      3. 4.4.3 Phase III
      4. 4.4.4 Phase IV
    5. 4.5 Healthcare, BY Geographical Focus (USD Billion)
      1. 4.5.1 Western Europe
      2. 4.5.2 Northern Europe
      3. 4.5.3 Southern Europe
      4. 4.5.4 Eastern Europe
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 IQVIA (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Covance (GB)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 PAREXEL International (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Charles River Laboratories (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Syneos Health (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Medpace (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 PPD (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Clinipace (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Wuxi AppTec (CN)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 EUROPE MARKET ANALYSIS BY SERVICE TYPE
    3. 6.3 EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA
    4. 6.4 EUROPE MARKET ANALYSIS BY END USER
    5. 6.5 EUROPE MARKET ANALYSIS BY STUDY PHASE
    6. 6.6 EUROPE MARKET ANALYSIS BY GEOGRAPHICAL FOCUS
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY SERVICE TYPE, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY SERVICE TYPE, 2024 TO 2035 (USD Billion)
    15. 6.15 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
    17. 6.17 HEALTHCARE, BY END USER, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
    19. 6.19 HEALTHCARE, BY STUDY PHASE, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY STUDY PHASE, 2024 TO 2035 (USD Billion)
    21. 6.21 HEALTHCARE, BY GEOGRAPHICAL FOCUS, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY GEOGRAPHICAL FOCUS, 2024 TO 2035 (USD Billion)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY SERVICE TYPE, 2026-2035 (USD Billion)
      2. 7.2.2 BY THERAPEUTIC AREA, 2026-2035 (USD Billion)
      3. 7.2.3 BY END USER, 2026-2035 (USD Billion)
      4. 7.2.4 BY STUDY PHASE, 2026-2035 (USD Billion)
      5. 7.2.5 BY GEOGRAPHICAL FOCUS, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Europe Europe CRO Market Segmentation

Europe CRO Market By Service Type (USD Billion, 2026-2035)

  • Clinical Trials
  • Preclinical Services
  • Laboratory Services
  • Consulting Services

Europe CRO Market By Therapeutic Area (USD Billion, 2026-2035)

  • Oncology
  • Cardiology
  • Neurology
  • Infectious Diseases

Europe CRO Market By End User (USD Billion, 2026-2035)

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Medical Device Companies
  • Academic Institutions

Europe CRO Market By Study Phase (USD Billion, 2026-2035)

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Europe CRO Market By Geographical Focus (USD Billion, 2026-2035)

  • Western Europe
  • Northern Europe
  • Southern Europe
  • Eastern Europe

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035